Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective


CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of care first-line treatment for ER+/HER2-negative advanced breast cancer. Although CDK4/6 inhibitors prolong survival for these patients, resistance is inevitable and there is currently no clear standard next-line treatment. There is an urgent unmet need to dissect the mechanisms which drive intrinsic and acquired resistance to CDK4/6 inhibitors and endocrine therapy to guide the subsequent therapeutic decisions. We will review the insights gained from preclinical studies and clinical cohorts into the diverse mechanisms of CDK4/6 inhibitor action and resistance, and highlight potential therapeutic strategies in the context of CDK4/6 inhibitor resistance.

Type Journal
ISBN 2296-634X (Print) 2296-634X (Electronic) 2296-634X (Linking)
Authors Zhou, F. H.; Downton, T.; Freelander, A.; Hurwitz, J.; Caldon, C. E.; Lim, E.
Publisher Name Front Cell Dev Biol
Published Date 2023-03-31
Published Volume 11
Published Pages 1148792
Status Published in-print
DOI 10.3389/fcell.2023.1148792
URL link to publisher's version